To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,

Sub: Press Release

▪▪▪

With reference to above subject, please find enclosed Press Release of our company titled **"Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA"**.

This is for your information and record.

Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**

K. Hanumantha Rao
Company Secretary

News Release

Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA.

HYDERABAD, INDIA (June 1st, 2018) – Suven Life Sciences Ltd (Suven) is participating and presenting positive Preclinical and Phase-1 clinical data of advanced molecules from their portfolio of new chemical entities (NCEs) at **Sleep 2018**, **A Joint Meeting Of The American Academy Of Sleep Medicine And The Sleep Research Society** being held at Baltimore, MD, USA during 2-6th June 2018.

SLEEP is the premier world forum to present and discuss the latest developments in clinical sleep medicine and sleep and circadian science.

The SLEEP meeting provides evidence-based education to advance the science and clinical practice of sleep medicine, disseminates cutting-edge sleep and circadian research, promotes the translation of basic science into clinical practice.

During the conference Suven will present their Phase 2 ready differentiated Clinical stage therapeutic candidate SUVN-G3031 (Histamine-3 receptor antagonist) for the treatment of Narcolepsy and Narcolepsy associated with Cataplexy. Narcolepsy is a commercially attractive space with a large unmet need. The data presentation highlight Suven's continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets.

About Suven Life Sciences
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and ongoing Phase 1 for SUVN-911.

In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at http://www.suven.com

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.